Varenicline tartrate tablets are indicated as an aid to smoking cessation. The drug’s mechanism involves binding with high affinity to α4β2 neuronal nicotinic acetylcholine receptors, simultaneously preventing nicotine binding and blocking the central nervous mesolimbic dopamine system. Studies demonstrated efficacy in 3659 chronic cigarette smokers across six clinical trials, with a 65% completion rate. Patients initiated treatment one week prior to their target quit date, starting with 0.5 mg once daily for days 1-3, escalating to 0.5 mg twice daily for days 4-7, and continuing with 1 mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for successful quitters. Patients received educational materials and counseling at weekly visits. Age ranges for participants were primarily between 43 and 75 years, with an average smoking history of approximately 25 years. Pharmacokinetics show a 90% systemic availability and a 24-hour elimination half-life. The drug exhibits minimal metabolism and low plasma protein binding. Specific populations, including elderly patients (65-75 years), pediatric patients (16 years and younger) are not recommended. Severe renal impairment (creatinine clearance <30 mL/min) requires a reduced starting dose. Varenicline’s efficacy was demonstrated in studies evaluating cardiovascular disease, COPD, and previous failed attempts at cessation.